Journey Medical (DERM) Cash & Equivalents (2020 - 2026)

Journey Medical has reported Cash & Equivalents for 7 years, with the latest figure at $27.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 29.18% year-over-year to $27.2 million; the trailing twelve-month figure through Mar 2026 stood at $27.2 million (up 29.18% YoY), and the FY2025 full-year result was $24.1 million, up 18.69% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $27.2 million, up from $24.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $41.3 million in Q1 2022, with the low at $8.2 million in Q2 2023.
• Historically, Cash & Equivalents has averaged $25.9 million across 5 years, with a median of $24.7 million in 2023.
• Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 78.48% — and 2024, when it soared 191.46%.
• Journey Medical's Cash & Equivalents stood at $32.0 million in 2022, then dropped by 14.25% to $27.4 million in 2023, then slipped by 26.0% to $20.3 million in 2024, then increased by 18.69% to $24.1 million in 2025, then advanced by 12.94% to $27.2 million in 2026.
• The last three Cash & Equivalents figures came in at $27.2 million (Q1 2026), $24.1 million (Q4 2025), and $24.9 million (Q3 2025), per Business Quant data.